Codagenix Inc., a US-based clinical-stage synthetic biology company, announced on Tuesday that it has named Kimber Poffenberger, PhD as its new chief strategy officer.
Dr Poffenberger has more than 20 years of strategic and regulatory leadership experience at pharma and biotech companies. She has held the position of principal consultant at Poffenberger Regulatory Resources, senior vice president, head of Global Regulatory Affairs at Alvotech, vice president and regional US head, Global Regulatory Affairs at GSK Vaccines and as executive director, Global Vaccines Strategy at Merck. Dr Poffenberger has also served in various leadership positions at Intercell, MedImmune, and Iomai Corporation.
J Robert Coleman, PhD, MBA, Codagenix,co-founder and CEO, said, 'We are excited to welcome Kimber to Codagenix. With her distinguished track record of driving global vaccine development and history of successfully leading cross-business strategic teams, she will provide an invaluable perspective to our organisation as we continue to develop our deep clinical pipeline of live attenuated vaccines and cancer virotherapeutics. Kimber brings extensive regulatory and product expertise, which will be critical as we work to bring our medicines to the patients who need them most.'
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine